A phase II, multicenter, randomized, open-label study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxethane in adult male patients with PSMA-positive metastatic castration-resistant prostate cancer
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: II
- Execution start: 29/09/2025
- End of execution: 30/11/2028
- PI: RAQUEL LUQUE CARO
